Louise-Marie CHEVALIER

Institut de Cancérologie de l'Ouest

France

Research Interests

Explore related searches

Professors in France Professors in Cancer Biology Cancer Biology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2023

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (9)

Judith Nzoughet Kouassi

Assistant Professor in Analytical Chemistry

Université Paris-Saclay

FRANCE

View details

Paul Kuentz

Professeur des Universités-Praticien Hospitalier

Centre Hospitalier Universitaire Vaudois

FRANCE

View details

Richard Redon

INSERM

FRANCE

View details

Caroline Rooryck

University of Bordeaux

FRANCE

View details

Eric Pasmant

Head

Institut Curie

FRANCE

View details

Sarah Baer

Chief of resident

Hôpitaux universitaires de Strasbourg

FRANCE

View details

Pierre Vande Perre

Institut Claudius Regaud

FRANCE

View details

Hélène Cavé

PUPH, Head of the molecular Genetics unit

Hôpital Robert-Debré

FRANCE

View details

Anne Patsouris

Institut de Cancérologie de l'Ouest

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Louise-Marie CHEVALIER

Research Interests

Explore related searches

Contact this professor

Articles (10)

<i>PFMG2025</i>-integrating genomic medicine into the national healthcare system in France.

Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER+/HER2- breast cancer and selected genomic alterations: results of the DOLAF trial.

Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes

A Case Report of Successful treatment with Crizotinib to overcome resistance to Osimertinib in an EGFR mutated non small cell lung cancer patient harboring an acquired MET Exon 14 mutation.

Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors

Lactic Acidosis Together with GM-CSF and M-CSF Induces Human Macrophages Toward an Inflammatory Protumor Phenotype

[Genetic instability, a factor limiting the efficiency of targeted therapies in solid oncology].

Non-Small-Cell Lung Cancer-Sensitive Detection of the p.Thr790Met EGFR Alteration by Preamplification before PNA-Mediated PCR Clamping and Pyrosequencing.

[EGFR molecular characterization in non-small cell bronchic cancer: comparative prospective study by NGS and Idylla platform technologies].

Collaborators (9)

Judith Nzoughet Kouassi

Paul Kuentz

Richard Redon

Caroline Rooryck

Eric Pasmant

Sarah Baer

Pierre Vande Perre

Hélène Cavé

Anne Patsouris

Make your next move.

Louise-Marie CHEVALIER

Research Interests

Explore related searches

Contact this professor

Articles (10)

&lt;i&gt;PFMG2025&lt;/i&gt;-integrating genomic medicine into the national healthcare system in France.

Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER+/HER2- breast cancer and selected genomic alterations: results of the DOLAF trial.

Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes

A Case Report of Successful treatment with Crizotinib to overcome resistance to Osimertinib in an EGFR mutated non small cell lung cancer patient harboring an acquired MET Exon 14 mutation.

Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors

Lactic Acidosis Together with GM-CSF and M-CSF Induces Human Macrophages Toward an Inflammatory Protumor Phenotype

[Genetic instability, a factor limiting the efficiency of targeted therapies in solid oncology].

Non-Small-Cell Lung Cancer-Sensitive Detection of the p.Thr790Met EGFR Alteration by Preamplification before PNA-Mediated PCR Clamping and Pyrosequencing.

[EGFR molecular characterization in non-small cell bronchic cancer: comparative prospective study by NGS and Idylla platform technologies].

Collaborators (9)

Judith Nzoughet Kouassi

Paul Kuentz

Richard Redon

Caroline Rooryck

Eric Pasmant

Sarah Baer

Pierre Vande Perre

Hélène Cavé

Anne Patsouris

Make your next move.

<i>PFMG2025</i>-integrating genomic medicine into the national healthcare system in France.